相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1924
已完成
3
50.0%
Unknown
2
33.3%
撤回
1
16.7%
暂无批准数据
- November 2025 marks 25 years since the FDA approved vascular brachytherapy for treating in-stent coronary artery restenosis, a condition that can re-narrow arteries after stent placement. - The breakthrough began with pioneering research in 1994 by Dr. Paul Teirstein at Scripps Clinic and Dr. Ron Waksman at Emory University, using Iridium-192 seeds in nylon ribbons. - Both the Novoste Beta-Cath System and Cordis's Iridium-192-based therapy received FDA approval on November 3, 2000, making vascular brachytherapy officially available for clinical use. - Best Vascular/Novoste continues as a global leader in vascular brachytherapy and is expanding applications while inviting collaboration on new VBT advancements.
- Solo Pace Incorporated has received FDA clearance for its SoloPace Control System, designed specifically for temporary pacing during Transcatheter Aortic Valve Replacement procedures. - The system features standardized workflows, operator-specific protocols, and automated pace capture checks that aim to improve procedural efficiency and reduce patient risks during TAVR procedures. - Initial human cases were successfully completed at Scripps Clinic by cardiologists Dr. Paul Teirstein and Dr. Curtiss Stinis, demonstrating the system's ability to simplify procedures and reduce staff workload.
